A PYMNTS Company

UK: Pharma firms accused of illegal agreements

By  |  February 28, 2019

The Competition and Markets Authority (CMA) has provisionally found that, from July 2011 to April 2015, the sole supplier of hydrocortisone tablets in the UK, Auden Mckenzie, and its rival, Waymade, entered into anti-competitive agreements.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    This may also have involved Auden Mckenzie abusing its dominant position by making monthly payments to Waymade not to enter the market. The CMA has today issued its concerns in a ‘Statement of Objections’ to the companies involved.

    As a result of this alleged anti-competitive behavior, the CMA believes the NHS was denied a choice of suppliers and the potential savings resulting from increased competition.

    Full Content: Gov UK

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.